U.S. Markets closed

Isoray, Inc. (ISR)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.0300-0.0100 (-0.96%)
At close: 4:00PM EDT

1.0200 -0.01 (-0.97%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0400
Open1.0200
Bid1.0000 x 1000
Ask1.0300 x 900
Day's Range0.9880 - 1.0400
52 Week Range0.3500 - 2.8100
Volume1,306,353
Avg. Volume15,833,616
Market Cap145.436M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0460
Earnings DateFeb 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.17
  • Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing
    GlobeNewswire

    Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

    RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort’s appointment adds key expertise. “I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray.” Woods concluded, “We believe Donna’s proven dedication to optimizing corporate success will make a valuable contribution as we continue to pursue opportunities to expand Cesium-131 brachytherapy treatment applications throughout the body and build Isoray’s position in our core prostate business.” Donna Fort’s extensive experience spans both biotechnology and medical device companies with an emphasis in oncology radioactive isotopes and monoclonal antibody technology. Fort has been with five start-up companies, having launched numerous complex multi-disciplinary products, including three radioactive isotopes for cancer. Fort joins Isoray following nine years with Sirtex Medical, where she held numerous management positions in the U.S. Most recently, she served as Executive Vice President, Sales & Marketing-Asia Pacific. In that capacity, she achieved substantial growth while managing the commercial business in eleven countries. In addition, Fort successfully streamlined efficiencies in the sales process and attained enhanced customer and patient experience by shortening the time to treat. Fort’s background also includes more than seven years with Johnson & Johnson, where she received numerous sales accolades and was recognized as the top performer in the immunology franchise of Centocor/Janssen. She is a graduate of the Johnson & Johnson Leadership Development Program and was the recipient of numerous leadership team awards. Commenting on the departure of Senior Vice President of Sales and Marketing Michael Krachon Woods said, “We appreciate Michael’s service to the Company, and we wish him well in his future endeavors.” About Isoray Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting www.isoray.com. Join us on LinkedIn and Facebook and follow us on Twitter. Safe Harbor Statement. Statements in this news release about Isoray's future expectations, including whether the hiring of Ms. Fort will result in the successful identification and consummation of growth opportunities in the Company’s core prostate business as well as in the treatment of other cancers and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether the anticipated growth opportunities will be identified and achieved. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910

  • Benzinga

    IsoRay's Cesium-131 And Surgical Resection Shows Promise In Recurrent Head & Neck Cancer

    According to a recently published small pilot study of patients with recurrent head and neck cancers treated with surgical resection and IsoRay Inc's (NYSE: ISR), Cesium-131 brachytherapy showed potential benefits that could support further research into combination therapy. This study's primary findings include the fact that re-treatment of recurrent head and neck cancers with surgical resection and Cesium-131 brachytherapy appears safe and feasible. Study authors noted that brachytherapy provides the possibility of optimal dose conformity with sharp dose fall-off that limits radiation dose to normal tissues, leading to fewer side effects compared to external beam radiation therapy. It was also noted that brachytherapy performed at the time of surgery is convenient for patients who would otherwise require 4-6 weeks of wound healing followed by 6-7 weeks of daily treatment with external beam radiation therapy. Additionally, an acceptable rate of cancer recurrence inside the field of the Cesium-131 implant area was observed – one out of twelve and was distant to the area of the Cesium-131 implant. The overall survival in this small series of patients was similar to those treated with a prolonged course of external beam radiation therapy. Price Action: ISR shares are up 2.8% at $1.11 in the premarket session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaAptorum ALS-4 Study Starts Dosing In Healthy VolunteersOutlook Therapeutics' Bevacizumab-vikg Shows Favorable Safety Profile In Retinal Disease Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
    GlobeNewswire

    University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection

    RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. The prospective series was conducted at the University Hospitals Cleveland Medical Center and involved 12 patients who were consented to an IRB-approved protocol that began accruing patients in 2016. The research team was led by Dr. Min Yao, Department of Radiation Oncology, and Dr. Chad Zender, Department of Otolaryngology Head and Neck Surgery, University Hospitals Cleveland Medical Center. Yao is also a professor in the radiology department of the Case Western Reserve School of Medicine, and Zender is an associate professor at the Case Western Reserve School of Dental Medicine and in the department of otolaryngology at the University of Cincinnati. The primary findings of this study include the fact that re-treatment of recurrent head and neck cancers with surgical resection and Cesium-131 brachytherapy appears safe and feasible. This finding is especially important due to the potential complications that follow re-irradiation of recurrent head and neck cancer using external beam radiation therapy (EBRT). Study authors noted that brachytherapy provides the possibility of optimal dose conformity with sharp dose fall-off that limits radiation dose to normal tissues, leading to fewer side effects compared to EBRT. They also noted that brachytherapy performed at the time of surgery is convenient for patients, who would otherwise require 4-6 weeks of wound healing followed by 6-7 weeks of daily treatment with EBRT. In addition, this small series found an acceptable rate of cancer recurrence inside the field of the Cesium-131 implant area – one out of twelve. The recurrence of most patients in this series was distant to the area of the Cesium-131 implant. The overall survival in this small series of patients were similar to those treated with a prolonged course of EBRT. Dr. Min Yao said, “While this was a small prospective study, the findings are in line with several retrospective and prospective studies that have reported the feasibility of brachytherapy in postoperative re-irradiation in recurrent head and neck cancers. Further research exploring the combination of immunotherapy and Cs-131 implant is warranted. We are proud to continue our legacy as innovators committed to researching promising therapies to bring opportunities to patients through medical advancements and the very best in care.” Commenting on the study, Isoray CEO Lori Woods said, “Looking to the future and bringing together the promise of Cesium-131 with surgical resection and immunotherapy represents what could prove to be a central moment in the treatment of head and neck cancer. We continue to strive to bring new brachytherapy treatment opportunities to the forefront to benefit patients and the medical professionals who care for them. This is yet another example of the commitment we have made as leaders in the field of brachytherapy.” With over 66,600 new cases diagnosed in the U.S. every year and over 14,000 deaths a year, cancers of the head and neck represent a significant source of mortality and cancer-related morbidity. Cancers of the head and neck recur frequently following initial treatment, which typically involves a regimen of surgical resection, radiation treatment, and chemotherapy. The anatomy of the head and neck is complex. It includes structures related with speech and swallowing and also critical structures such as spinal cord and carotid artery. As a result, re-treatment with external beam radiation treatment becomes problematic due to the limited amount of radiation that can be administered to the area without giving rise to serious complications. Brachytherapy with Cesium-131 offers a source of potentially effective radiation therapy for recurrent head and neck cancers due to the highly compact dose delivered by Cesium-131 implants. Cesium-131 is capable of delivering high doses of radiation to the cancerous target following surgical resection in such a way that keeps the important anatomic structures of the head and neck from receiving damaging radiation. Isoray is a medical technology company and innovator in seed brachytherapy. The Company is the world’s only producer of Cesium-131 brachytherapy, commercially known as Cesium Blu, which is powering expanding internal radiation treatment options throughout the body for difficult to treat head and neck, lung, brain, gynecological, pelvic, and colorectal cancers as well as prostate cancer. About IsorayIsoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium -131, commercially known as Cesium Blu, brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting www.isoray.com. Join us on LinkedIn and Facebook and follow us on Twitter. Safe Harbor StatementStatements in this news release about Isoray’s future expectations, including whether the study discussed in this news release will be successful and have favorable outcomes, the advantages of Cesium-131 and its delivery systems coupled with immunotherapy, the perception by patients of quality of life outcomes compared to other treatment options, whether demand for and use of Cesium-131 will increase or continue as anticipated and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the impact of COVID-19 on our financial results, suppliers, employees and scheduling of procedures, whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results, physician acceptance, training and use of our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, and other risks detailed from time to time in Isoray’s reports filed with the U.S. Securities Exchange Commission. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910